Risk assessment and risk management of novel plant foods:Concepts and principles

Novel food regulation is already in force in the European Community, Australia/New Zealand and in Canada. These regulations distinguish between traditional plant foods and novel plant foods, as the novel plant foods need to go through a premarket assessment procedure. This report focus on developing a proposal for definitions and criteria for determining if a plant food is traditional or novel and a proposal for an approach for the safety assessment of such plant foods with no or limited documented history of safe consumption. The report recommend to introduce a 2-step management procedure, first to establish the novelty and secondly to define and commit resources for the safety assessment, and recommend to generate and use a worldwide net of global, regional, local and ethnobotanical positive lists for food plants to guide both the decision on novelty and the safety assessment. The report recommends using the "history of use"-concept and if the data submitted can support the claim that a product has a history of safe use, the approval can be straightforward. In Europe around 300 food plants deliver near 100% of human daily intake of plant food calories while nearly 7,000 other food plant species are used in other parts of the world. This report focuses on the situation when novel food items from these 7,000 plants are to enter the European or other regional market

Matrix Metalloproteinase 13 Is Induced in Fibroblasts in Polyomavirus Middle T Antigen-Driven Mammary Carcinoma without Influencing Tumor Progression

Matrix metalloproteinase (MMP) 13 (collagenase 3) is an extracellular matrix remodeling enzyme that is induced in myofibroblasts during the earliest invasive stages of human breast carcinoma, suggesting that it is involved in tumor progression. During progression of mammary carcinomas in the polyoma virus middle T oncogene mouse model (MMTV-PyMT), Mmp13 mRNA was strongly upregulated concurrently with the transition to invasive and metastatic carcinomas. As in human tumors, Mmp13 mRNA was found in myofibroblasts of invasive grade II and III carcinomas, but not in benign grade I and II mammary intraepithelial neoplasias. To determine if MMP13 plays a role in tumor progression, we crossed MMTV-PyMT mice with Mmp13 deficient mice. The absence of MMP13 did not influence tumor growth, vascularization, progression to more advanced tumor stages, or metastasis to the lungs, and the absence of MMP13 was not compensated for by expression of other MMPs or tissue inhibitor of metalloproteinases. However, an increased fraction of thin collagen fibrils was identified in MMTV-PyMT;Mmp13−/− compared to MMTV-PyMT;Mmp13+/+ tumors, showing that collagen metabolism was altered in the absence of MMP13. We conclude that the expression pattern of Mmp13 mRNA in myofibroblasts of invasive carcinomas in the MMTV-PyMT breast cancer model recapitulates the expression pattern observed in human breast cancer. Our results suggest that MMP13 is a marker of carcinoma-associated myofibroblasts of invasive carcinoma, even though it does not make a major contribution to tumor progression in the MMTV-PyMT breast cancer model

Back-illuminated Si photocathode:a combined experimental and theoretical study for photocatalytic hydrogen evolution

We present the first experimental demonstration of c-Si based photocathode for hydrogen production under back-illumination with theoretical model study.</p